FDA Clears MiniMed Fit Tubeless Insulin Pump with Seven-Day Wear
Vandana Singh 4 hours ago
Trading IdeasMoversNewsFDAGeneralHealth Care
MiniMed secures FDA clearance for MiniMed Fit, its first tubeless insulin pump offering seven-day wear and automated SmartGuard technology.
MiniMed (NASDAQ:MMED) on Monday secured U.S. Food and Drug Administration clearance for MiniMed Fit, marking the company’s debut in the tubeless insulin pump market with a device offering up to seven days of wear and a 300-unit insulin capacity.
• Minimed Group shares are climbing with conviction. What’s driving MMED stock higher?
The FDA cleared the discreet, waterproof system for people ages seven and older with Type 1 and Type 2 diabetes.
By providing up to double the wear time and 50% more insulin capacity than competing tubeless pumps, MiniMed Fit reduces pump changes, minimizes daily interruptions and simplifies routine diabetes management decisions.
Automated Insulin Delivery and Sensor Options
Users operate the tubeless pump directly through a mobile app on compatible iOS and Android devices.
SmartGuard technology automates insulin delivery by adjusting doses and administering correction insulin every five minutes, while Meal Detection technology provides additional insulin whenever users miss or underestimate a meal dose.
Real-world users following recommended SmartGuard settings have reached up to 80% Time in Range and 91% overnight Time in Range, helping them stay within target glucose levels.
At commercial launch, patients can pair the system with either the Simplera Sync sensor for up to seven days of wear or Abbott’s Instinct sensor for up to 15 days.
Flexible Wear and Spring 2027 Rollout
Patients can apply MiniMed Fit comfortably across five wear locations: the abdomen, thigh, upper buttocks, lower back and back of the arm.
The pump supports Humalog, NovoLog, and Admelog insulins, and patients will obtain the device conveniently through the pharmacy channel.
MiniMed expects an early customer experience phase to begin in the fourth quarter of its fiscal year 2027 before initiating a phased U.S. rollout in spring 2027.
The company is also planning integration with its investigational next-generation fully closed-loop technology.
MMED Price Action: MiniMed shares were up 3.70% at $18.65 at the time of publication on Monday, according to Benzinga Pro data.
Photo via MiniMed
